Male contraception startup closes $92.5M Series B; Novartis bets on actinium

June 2, 2026 10:43 AM EDT News Briefing Male con­tra­cep­tion start­up clos­es $92.5M Se­ries B; No­var­tis bets on ac­tini­um in Phase 3 ENDPOINTS 💸 Fund­ing male con­tra­cep­tion: Con­tra­line closed a $92.5 mil­lion Se­ries B fi­nanc­ing to sup­port a Phase 3 study of a male con­tra­cep­tive dubbed NES/T. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER